Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Once-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation
Extended-Release formulation was well tolerated, with the safety profile. | April 5, 2023
Capital of less than $100 is enough to buy one of these three promising growth stocks that don't belong to the technology sector. Capital of less than $100 is enough to buy one of these three promising growth stocks that don't belong to the technology sector.